Clinical trials
Head and Neck Carcinoma clinical trials
Below are recruiting head and neck carcinoma clinical trials, each written for real people, not researchers. We’re tracking 503 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05710679Recruiting
Blood test predicts leftover cancer after intensified head and neck radiation
This study uses a blood test to see whether cancer DNA is still detectable after a stronger combination of radiation and chemotherapy for locally advanced head and neck cancer. The goal is to predict who may have “residual” (remaining) disease and help guide future care.
Clermont-Ferrand, Puy-de-DômeAges 18–80 - NCT05707078Recruiting
PET/CT follow-up for head and neck cancer
This study uses a PET/CT scan (a special scan that can look for signs of cancer activity) after curative treatment for head and neck squamous cell cancer. It aims to help check how well prior treatment is working and whether cancer may come back.
Copenhagen, CopenhagenAges 18 years+ - NCT05674396RecruitingPhase 2
Short-course radiation to ease symptoms from head and neck cancer
This Phase 2 trial tests a specific, shorter type of focused radiation to help relieve symptoms from head and neck squamous cell carcinoma. It compares two radiation timing/planning approaches to see which better improves comfort and quality of life.
Houston, TexasAges 18 years+ - NCT05576974RecruitingPhase 2
Test a dye used during surgery to find head and neck cancer
This trial tests whether a single dose of an imaging dye (given during surgery) can help doctors find the unknown origin of head and neck cancer and check safety. It may help guide surgery and biopsies when the primary cancer location hasn’t been identified.
Dallas, TexasAges 18–99 - NCT05553782RecruitingEarly Phase 1
IMD device study for certain head and neck cancers
This early-phase study tests a new small device (placed through the skin) plus standard surgery to study head and neck cancers. It may help researchers understand how the device works and gather safety information for people who need definitive surgery for a measurable tumor.
Boston, MassachusettsAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05544136RecruitingPhase 2
Study of lower radiation and chemo for head and neck cancer
This study tests whether giving lower doses of radiation and chemotherapy is safe and effective for people with certain head and neck cancers. It aims to reduce side effects while keeping the treatment successful.
Basking Ridge, New JerseyAges 18 years+ - NCT05526924RecruitingPhase 1
Phase 1 trial tests re-radiation plus immunotherapy and a cancer pill
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
Chicago, IllinoisAges 18 years+ - NCT05420948RecruitingPhase 2
Pembrolizumab with chemotherapy for returning or spread head cancer
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
Chicago, IllinoisAges 18 years+ - NCT05376553Enrolling by invitationPhase 1
Test cemiplimab plus chemo before treatment for head and neck cancer
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
New York, New YorkAges 18 years+ - NCT05328024Recruiting
Testing who benefits from anti–PD-1 immunotherapy in head cancer
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
Strasbourg, FranceAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05172245RecruitingPhase 1
Testing a new drug added to chemoradiation for head and neck cancer
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
Tampa, FloridaAges 18 years+ - NCT05187091RecruitingPhase 3
Radiation plan that tries to protect swallowing organs
This Phase 3 study compares a standard radiation approach versus a modified approach designed to spare key swallowing and aspiration (choking) related areas and one salivary gland. It may help reduce treatment side effects that affect swallowing and quality of life for certain head and neck cancer patients.
Jhajjar, HaryanaAges 18–70 - NCT05183048RecruitingEarly Phase 1
Test a new PET scan to find head and neck cancer
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
Birmingham, AlabamaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05031910Recruiting
Virtual 3D guidance for head and neck cancer surgery
This study tests whether a virtual reality (3D computer) model of surgery can help surgeons improve how head and neck cancer operations are planned and done. You may benefit from more personalized surgical planning, if you’re eligible for standard surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04528420Recruiting
Early treatment plan for head and neck skin cancer
This study tests an optimized plan for treating squamous cell cancer in the head and neck area using curative treatment that includes chemotherapy with cisplatin plus radiation after surgery. It may help doctors improve early management and outcomes for people eligible for this standard approach.
AmiensAges 18–75
Hear when a new Head and Neck Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for head and neck carcinoma?
- Yes. Clin2 currently lists 503 recruiting head and neck carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a head and neck carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a head and neck carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer Squamous Cell Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Resectable Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.